{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:52:24Z","timestamp":1781761944556,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01783-1","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:06:52Z","timestamp":1779509212000},"page":"3445-3460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Criteria for Hidradenitis Suppurativa Competence Centers"],"prefix":"10.1007","volume":"16","author":[{"given":"Angelo V.","family":"Marzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessel H.","family":"Van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel P.","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thrasyvoulos","family":"Tzellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha Suyien","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne P. F.","family":"Gulliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cecilia","family":"Rivitti-Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Wortsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry M.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Pintori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Alarcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2608","authenticated-orcid":false,"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"1783_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1203475420972348","volume":"25","author":"M Sachdeva","year":"2021","unstructured":"Sachdeva M, Shah M, Alavi A. Race-specific prevalence of hidradenitis suppurativa. J Cutan Med Surg. 2021;25:177\u201387.","journal-title":"J Cutan Med Surg"},{"issue":"8","key":"1783_CR2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","volume":"153","author":"A Garg","year":"2017","unstructured":"Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760\u20134.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1783_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juh\u00e1sz I, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Suppl 1","key":"1783_CR4","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jaad.2015.07.052","volume":"73","author":"GB Jemec","year":"2015","unstructured":"Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4-7.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1783_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/bjd.16101","volume":"178","author":"JR Ingram","year":"2018","unstructured":"Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917\u201324.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1783_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","volume":"157","author":"A Jfri","year":"2021","unstructured":"Jfri A, Nassim D, O\u2019Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021;157(8):924\u201331.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1783_CR7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjd.19435","volume":"183","author":"JR Ingram","year":"2020","unstructured":"Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990\u20138.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1783_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.clindermatol.2023.08.020","volume":"41","author":"Z Bukvi\u0107 Mokos","year":"2023","unstructured":"Bukvi\u0107 Mokos Z, Markota \u010cagalj A, Marinovi\u0107 B. Epidemiology of hidradenitis suppurativa. Clin Dermatol. 2023;41(5):564\u201375.","journal-title":"Clin Dermatol"},{"issue":"10476","key":"1783_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420\u201338.","journal-title":"Lancet"},{"key":"1783_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00068","volume":"7","author":"SM Seyed Jafari","year":"2020","unstructured":"Seyed Jafari SM, Hunger RE, Schlapbach C. Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm. Front Med. 2020;7:68.","journal-title":"Front Med"},{"issue":"12","key":"1783_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.14214","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa\u202f?-15 years after. Exp Dermatol. 2020;29(12):1154\u201370.","journal-title":"Exp Dermatol"},{"issue":"Suppl 1","key":"1783_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/exd.14341","volume":"30","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC, Goyal M, Byrd AS. Hidradenitis suppurativa in skin of colour. Exp Dermatol. 2021;30(Suppl 1):27\u201330.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1783_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40257-014-0105-5","volume":"16","author":"A Alavi","year":"2015","unstructured":"Alavi A, Anooshirvani N, Kim WB, Coutts P, Sibbald RG. Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol. 2015;16(1):61\u20135.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1783_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","volume":"56","author":"P Wolkenstein","year":"2007","unstructured":"Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J, Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1783_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","volume":"62","author":"\u0141 Matusiak","year":"2010","unstructured":"Matusiak \u0141, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010;62(4):706-708,708.e1.","journal-title":"J Am Acad Dermatol"},{"key":"1783_CR16","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.2485","volume":"103","author":"M Otten","year":"2023","unstructured":"Otten M, Augustin M, Blome C, Topp J, Niklaus M, Hilbring C, et al. Measuring quality of life in hidradenitis suppurativa: development and validation of a disease-specific patient-reported outcome measure for practice and research. Acta Derm Venereol. 2023;103:adv00859.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1783_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2382372","volume":"56","author":"N Abu Rached","year":"2024","unstructured":"Abu Rached N, R\u00fcth J, Gambichler T, Ocker L, Bechara FG. A state-of-the-art systematic review of cancer in hidradenitis suppurativa. Ann Med. 2024;56(1):2382372.","journal-title":"Ann Med"},{"issue":"7","key":"1783_CR18","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.3390\/ijms24076596","volume":"24","author":"N Abu Rached","year":"2023","unstructured":"Abu Rached N, Gambichler T, Ocker L, Dietrich JW, Quast DR, Sieger C, et al. Screening for diabetes mellitus in patients with hidradenitis suppurativa: a monocentric study in Germany. Int J Mol Sci. 2023;24(7):6596.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"1783_CR19","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.3390\/jcm12237490","volume":"12","author":"N Abu Rached","year":"2023","unstructured":"Abu Rached N, Dietrich JW, Ocker L, Quast DR, Scheel C, Gambichler T, et al. Primary thyroid dysfunction is prevalent in hidradenitis suppurativa and marked by a signature of hypothyroid graves\u2019 disease: a case-control study. J Clin Med. 2023;12(23):7490.","journal-title":"J Clin Med"},{"issue":"1","key":"1783_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010044","volume":"14","author":"VA Zouboulis","year":"2021","unstructured":"Zouboulis VA, Zouboulis KC, Zouboulis CC. Hidradenitis suppurativa and comorbid disorder biomarkers, druggable genes, new drugs and drug repurposing - a molecular meta-analysis. Pharmaceutics. 2021;14(1):44.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1783_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1783_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1783_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjd.21247","volume":"187","author":"A Di Cesare","year":"2022","unstructured":"Di Cesare A, Nikolakis G, Kanni T, Giamarellos-Bourboulis EJ, Matusiak L, Szepietowski JC, et al. Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study. Br J Dermatol. 2022;187(3):428\u201330.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1783_CR24","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1111\/jdv.13687","volume":"30","author":"V Bettoli","year":"2016","unstructured":"Bettoli V, Pasquinucci S, Caracciolo S, Piccolo D, Cazzaniga S, Fantini F, et al. The Hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities. J Eur Acad Dermatol Venereol. 2016;30(11):1965\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6S","key":"1783_CR25","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jaad.2024.09.008","volume":"91","author":"S Daveluy","year":"2024","unstructured":"Daveluy S, Okoye GA. Quality of life and the patient journey in hidradenitis suppurativa. J Am Acad Dermatol. 2024;91(6S):S8\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1783_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jdv.15233","volume":"33","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horv\u00e1th B, Hughes R, et al. Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1783_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, Bettoli V, Bukvi\u0107 Mokos Z, Del Marmol V, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2025;39:899\u2013941.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1783_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jaad.2024.11.071","volume":"92","author":"R Alhusayen","year":"2025","unstructured":"Alhusayen R, Dienes S, Lam M, Alavi A, Alikhan A, Aleshin M, et al. North American Clinical Practice Guidelines for the medical management of hidradenitis suppurativa in special patient populations. J Am Acad Dermatol. 2025;92(4):825\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"1783_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12913-017-2340-y","volume":"17","author":"JK Elrod","year":"2017","unstructured":"Elrod JK, Fortenberry JL Jr. Centers of excellence in healthcare institutions: what they are and how to assemble them. BMC Health Serv Res. 2017;17(Suppl 1):425.","journal-title":"BMC Health Serv Res"},{"issue":"Suppl 1","key":"1783_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/exd.14338","volume":"30","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, Jemec GBE, Del Marmol V, Marzano AV, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021;30(Suppl 1):8\u201317.","journal-title":"Exp Dermatol"},{"issue":"2","key":"1783_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2020.06.019","volume":"141","author":"JW Frew","year":"2021","unstructured":"Frew JW, Marzano AV, Wolk K, Join-Lambert O, Alavi A, Lowes MA, et al. A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol. 2021;141(2):316-324.e2.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1783_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/bjd\/ljad135","volume":"189","author":"M Schultheis","year":"2023","unstructured":"Schultheis M, Staubach P, Nikolakis G, Schollenberger L, Mauch M, Burckhardt M, et al. A centre-based ambulatory care concept for hidradenitis suppurativa improves disease activity, disease burden and patient satisfaction: results from the randomized controlled EsmAiL trial. Br J Dermatol. 2023;189(2):170\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1783_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000516308","volume":"7","author":"JR Seivright","year":"2021","unstructured":"Seivright JR, Thompson A, Hamzavi I, Lowes MA, Porter M, Shi VY, et al. Hidradenitis suppurativa specialty clinics in the USA. Skin Appendage Disord. 2021;7(5):359\u201362.","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"1783_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijwd.2020.02.006","volume":"6","author":"A Timila Touhouche","year":"2020","unstructured":"Timila Touhouche A, Chaput B, Marie Rouquet R, Montastier E, Caron P, Gall Y, et al. Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice. Int J Womens Dermatol. 2020;6(3):164\u20138.","journal-title":"Int J Womens Dermatol"},{"key":"1783_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jdin.2021.11.007","volume":"6","author":"I Toledo","year":"2022","unstructured":"Toledo I, Lee SS, Park HH, Vuong C, Conic RRZ, Hightower GK. A visit guide for adolescent hidradenitis suppurativa: bridging the divide between pediatric and adult care. JAAD Int. 2022;6:84\u20135.","journal-title":"JAAD Int"},{"key":"1783_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jdin.2023.01.021","volume":"11","author":"T Shih","year":"2023","unstructured":"Shih T, Lee K, Aleshin M, Bennett R, Mayo T, Okoye GA, et al. A practical guide to starting a hidradenitis suppurativa specialty clinic. JAAD Int. 2023;11:117\u201320.","journal-title":"JAAD Int"},{"issue":"9","key":"1783_CR37","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s00403-023-02645-y","volume":"315","author":"SA Chadha","year":"2023","unstructured":"Chadha SA, Stout MA, Goyal PK, Nguyen CV, Lu KQ. Assessing unmet needs in patients with hidradenitis suppurativa. Arch Dermatol Res. 2023;315(9):2555\u201360.","journal-title":"Arch Dermatol Res"},{"key":"1783_CR38","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2147\/CCID.S420750","volume":"16","author":"EA Bellei","year":"2023","unstructured":"Bellei EA, Shirozaki MEM, Puglia ALP, de Esteves Carvalho AV, Riquena B, Vallilo CC, et al. Requirements for Brazilian outpatient centers of excellence in hidradenitis suppurativa: consensus co-creative study. Clin Cosmet Investig Dermatol. 2023;16:2029\u201344.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1783_CR39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00403-024-03316-2","volume":"316","author":"AV Marzano","year":"2024","unstructured":"Marzano AV, Magnoni C, Micali G, De Magnis A, Pintori G, Fiorini S, et al. Improving hidradenitis suppurativa management: consensus statements from physicians and patients\u2019 perspectives. Arch Dermatol Res. 2024;316:577.","journal-title":"Arch Dermatol Res"},{"key":"1783_CR40","doi-asserted-by":"crossref","unstructured":"Hilhorst N, Deprez E, Roman E, Borz\u00e9e J, de Beule D, Dullaers C, Hoorens I; Lambert. PsoPlus: an integrated practice unit for psoriasis. Dermatology. 2023;239(3):334\u2013344.","DOI":"10.1159\/000529398"},{"issue":"2","key":"1783_CR41","doi-asserted-by":"publisher","first-page":"9278","DOI":"10.4081\/dr.2021.9278","volume":"13","author":"L Fania","year":"2021","unstructured":"Fania L, Massone C, Cusano F, Fantini F, Dellambra E, Samela T, et al. Integrated care pathways and the hub-and-spoke model for the management of non-melanoma skin cancer: a proposal of the Italian Association of Hospital Dermatologists (ADOI). Dermatol Rep. 2021;13(2):9278.","journal-title":"Dermatol Rep"},{"issue":"1062","key":"1783_CR42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/postgradmedj-2013-131994","volume":"90","author":"DN Dufour","year":"2014","unstructured":"Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90(1062):216\u201321.","journal-title":"Postgrad Med J"},{"issue":"1","key":"1783_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13555-020-00354-2","volume":"10","author":"T Tzellos","year":"2020","unstructured":"Tzellos T, Zouboulis CC. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther. 2020;10(1):63\u201371.","journal-title":"Dermatol Ther"},{"key":"1783_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/derm.2.1.12490","volume":"2","author":"S Fimmel","year":"2010","unstructured":"Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2:9\u201316.","journal-title":"Dermatoendocrinol"},{"issue":"5","key":"1783_CR45","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"1783_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/exd.14633","volume":"31","author":"T Tzellos","year":"2022","unstructured":"Tzellos T, Zouboulis CC. Which hidradenitis suppurativa comorbidities should I take into account? Exp Dermatol. 2022;31(Suppl 1):29\u201332.","journal-title":"Exp Dermatol"},{"key":"1783_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20600","author":"X Wortsman","year":"2025","unstructured":"Wortsman X, Alfageme F, Dini V, Garc\u00eda-Mart\u00ednez FJ, Caposiena Caro RD, Frew J, et al. International consensus statement on the use of ultrasound in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20600.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 6","key":"1783_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/jdv.15850","volume":"33","author":"A Chiricozzi","year":"2019","unstructured":"Chiricozzi A, Micali G, Veraldi S. The patient journey: a voyage from diagnosis to hidradenitis suppurativa multidisciplinary unit. J Eur Acad Dermatol Venereol. 2019;33(Suppl 6):15\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1783_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041871","volume":"11","author":"KF Hjuler","year":"2021","unstructured":"Hjuler KF, Dige A, Agnholt J, et al. Effectiveness of interdisciplinary combined dermatology-gastroenterology-rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial. BMJ Open. 2021;11(4):e041871.","journal-title":"BMJ Open"},{"issue":"suppl 2","key":"1783_CR50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0001-7310(17)30007-8","volume":"107","author":"A Martorell","year":"2016","unstructured":"Martorell A, Caballero A, Gonz\u00e1lez Lama Y, Jim\u00e9nez-Gallo D, L\u00e1zaro Serrano M, Miranda J, et al. Management of patients with hidradenitis suppurativa. Actas Dermosifiliogr. 2016;107(suppl 2):32\u201342.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"1783_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, et al. Evidence for a \u201cwindow of opportunity\u201d in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133\u201340.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1783_CR52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.amjmed.2022.09.025","volume":"136","author":"A Garg","year":"2023","unstructured":"Garg A, Naik HB, Kirby JS. A practical guide for primary care providers on timely diagnosis and comprehensive care strategies for hidradenitis suppurativa. Am J Med. 2023;136(1):42\u201353.","journal-title":"Am J Med"},{"issue":"6S","key":"1783_CR53","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.jaad.2024.09.007","volume":"91","author":"CB Dagenet","year":"2024","unstructured":"Dagenet CB, Lee KH, Fragoso NM, Shi VY. Approach to the patient with hidradenitis suppurativa: evaluating severity to guide therapy. J Am Acad Dermatol. 2024;91(6S):S22\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"1783_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, del Marmol V, Mrowietz U, Prens E, Tzellos T, Jemec GBE. Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184\u201390.","journal-title":"Dermatology"},{"issue":"5","key":"1783_CR55","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/bjd\/ljad028","volume":"188","author":"P Mendes-Bastos","year":"2023","unstructured":"Mendes-Bastos P, Martorell A, Bettoli V, Matos AP, Muscianisi E, Wortsman X. The use of ultrasound and magnetic resonance imaging in the management of hidradenitis suppurativa: a narrative review. Br J Dermatol. 2023;188(5):591\u2013600.","journal-title":"Br J Dermatol"},{"key":"1783_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pdpdt.2018.05.007","volume":"23","author":"S Derruau","year":"2018","unstructured":"Derruau S, Renard Y, Pron H, Taiar R, Abdi E, Polidori G, et al. Combining magnetic resonance imaging (MRI) and medical infrared thermography (MIT) in the pre- and peri-operating management of severe hidradenitis suppurativa (HS). Photodiagnosis Photodyn Ther. 2018;23:9\u201311.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1783_CR57","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000495982","volume":"235","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Nogueira da Costa A, Jemec GBE, Trebing D. Long-wave medical infrared thermography (MIT): a clinical biomarker of inflammation in hidradenitis suppurativa\/acne inversa. Dermatology. 2019;235:144\u20139.","journal-title":"Dermatology"},{"issue":"6","key":"1783_CR58","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1159\/000524226","volume":"238","author":"W Boothby-Shoemaker","year":"2022","unstructured":"Boothby-Shoemaker W, Rehman R, Hamzavi I, Huggins RH, Mohammad TF. Recommendations to optimize patient care in hidradenitis suppurativa clinics: our experience. Dermatology. 2022;238(6):1104\u20137.","journal-title":"Dermatology"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01783-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:03:26Z","timestamp":1781759006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01783-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1783"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01783-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Angelo V Marzano reports consultancy\/advisory boards\u2019 disease-relevant honoraria from AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, Incyte, Johnson & Johnson, L\u2032Or\u00e9al, LEO Pharma, Novartis Pharma, Pfizer, Sanofi and UCB Pharma. Falk G Bechara received honoraria for participation in advisory boards in clinical trials and\/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Acelyrin, Beiersdorf, Boehringer-Ingelheim Pharma GmbH & Co. KG, Celltrion, Dr. Wolff, Incyte Corporation, Janssen-Cilag GmbH, Johnson & Johnson, Merck, M\u00f6lnlycke, MoonLake Immunotherapeutics, Novartis Pharma GmbH, Sanofi, Sitala and UCB Pharma. Vivian Y Shi is an Editorial Board member of Dermatology and Therapy. Vivian Y Shi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Vivian Y Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker and\/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Dermavant, Boehringer-Ingelheim, Almirall, Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt\u2019s Bees, Galderma, Kiniksa, UCB, Ceraclere, Bain Capital, Target-PharmaSolutions, Castle Bioscience, Altus Lab\/cQuell, MYOR, Polyfins Technology, GpSkin and Skin Actives Scientific. Antonio Martorell is a member of the European Hidradenitis Suppurativa Foundation and has acted as a consultant, advisory board member and investigator for and has received honoraria from, Incyte, Novartis, AbbVie, Pfizer, Johnson & Johnson, UCB Pharma, Lilly, LEO Pharma, L\u2019Or\u00e9al, Sanofi, Sandoz, Galderma Legit Health and Amgen. Jennifer L Hsiao is an Editor-in-Chief of Dermatology and Therapy. Jennifer L Hsiao was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jennifer L Hsiao is on the board of directors for the Hidradenitis Suppurativa Foundation and has served as an advisor, investigator and\/or speaker for AbbVie, Aclaris, Boehringer Ingelheim, Galderma, Incyte, Novartis, Sanofi Regeneron and UCB Pharma. Hessel H Van der Zee has received honoraria as speaker or as member of an advisory board for UCB Pharma, Novartis, AbbVie, Incyte, Sanofi, InflaRX and Insmed. Axel P Villani reports consulting fees from Janssen-Cilag; payment or honoraria from AbbVie, Almirall, BMS, Janssen-Cilag, LEO Pharma, Eli Lilly, MSD, Novartis and UCB Pharma; and support for attending meetings or travel from Janssen-Cilag and UCB Pharma. Afsaneh Alavi serves as the board member of the Hidradenitis Suppurativa Foundation, received grants from the NIH, HSF, La Roche-Posay, serves as the chair of Independent Data Monitoring: InflaRX, Almirall, Zura Bio and a consultant for AbbVie, Almirall, Avalo, BI, Cantargia, InflaRx, Incyte, LEO Pharma, Sanofi,\u00a0Navigator, Novartis and UCB Pharma and as an investigator for BI and Processa. John R Ingram is a consultant and\/or advisory board member for AbbVie, Boehringer Ingelheim, Cantargia, ChemoCentryx, Citryll, Elasmogen, Engitix, Incyte, Indero, Insmed, Kymera Therapeutics, MoonLake Immunotherapeutics, Novartis, UCB Pharma, UNION Therapeutics and Viela Bio; received stipend as immediate past-Editor-in-Chief of the\n                      British Journal of Dermatology\n                      and an author honorarium from UpToDate and is a co-copyright holder of HiSQOL and Investigator and Patient Global Assessment instruments for HS. His department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. Christopher J Sayed is a speaker for AbbVie, UCB Pharma and Novartis; has consulted for AbbVie, AstraZeneca, Novartis, InflaRx, UCB, Incyte, Sanofi, Navigator Medicines, Sonoma Biotherapeutics and Alumis; is an investigator for AbbVie, AstraZeneca, Novartis, InflaRx, UCB, Incyte and ChemoCentryx; has received grant funding from AbbVie; and is on the board of the HS Foundation, an unpaid position. Thrasyvoulos Tzellos reports consultancy\/advisory boards\/speaker fees from AbbVie, Novartis, Boehringer-Ingelheim, MSD and UCB Pharma. He is the treasurer of the EHSF e.V. Nisha Suyien Chandran has received fees for participation in advisory boards from fees from AbbVie, Johnson & Johnson, Sanofi, Pfizer, Novartis, L\u2019Or\u00e9al and DKSH for participation in advisory boards; investigator fees for clinical trials from AbbVie, Novartis, Amgen, Sanofi and Boehringer-Ingelheim; and speaker honoraria from Galderma, Johnson & Johnson, Janssen, LEO Pharma, Lion Corporation, Sanofi and Pfizer. Qiang Ju None to declare. Ichiro Kurokawa is an Editorial Board member of Dermatology and Therapy. Ichiro Kurokawa was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. John W Frew has conducted advisory work for Janssen, Boehringer Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, ChemoCentryx, AbbVie, Azora, Novartis and UCB; has participated in trials for Pfizer, UCB, Boehringer-Ingelheim, Eli Lilly, CSL and Azora; and has received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB and La Roche-Posay. Wayne PF Gulliver has received grants\/research support from AbbVie, Amgen, Eli Lilly, Novartis and Pfizer; honoraria for Ad Boards\/Invited Talks\/Consultation from AbbVie, Actelion, Amgen, Arylide, Bausch Health, Boehringer, Celgene, Cipher, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Novartis, PeerVoice, Pfizer, Sanofi-Genzyme, Tribute, UCB, Sun Pharma and Valeant; study fees for clinical trials (study fees) from AbbVie, Asana Biosciences, Astellas, Boehringer Ingelheim, Celgene, Corrona\/National Psoriasis Foundation, Devonian, Eli Lilly, Galapagos, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sun Pharma and UCB Pharma. Maria Cec\u00edlia\u00a0Rivitti-Machado reports consultancy\/speaker\/ad board fees from AbbVie, Ach\u00e9, Novartis, Janssen, Sanofi, Pfizer and UCB; support to attend meetings from AbbVie, Pfizer and Sanofi and investigator fees for clinical trials from AbbVie. Ximena Wortsman Speaker for Novartis and UCB and as a consultant for Galderma and received royalties from Springer. Barry M McGrath has received honoraria for consulting from Almirall, Incyte and MoonLake Immunotherapeutics and honoraria for consulting and participating in steering committees\/advisory boards, speaking engagements and educational events from Novartis and UCB Pharma, as well as support for attending meetings from Novartis and UCB Pharma. Giuseppina Pintori None to declare. Valeria Jordan, Nicolas Thomas and Ivette Alarcon are employees and stockholder of Novartis. Christos C Zouboulis reports consultancy\/advisory board\/lecture fee disease-relevant honoraria from Almirall, BMS, Boehringer Ingelheim, CLS Behring, Eli Lilly, Idorsia, Incyte, LEO Pharma, MSD, Novartis, Sanofi, ShiRhom, Takeda, UCB Pharma and Zura Bio. He is the president of the EHSF e.V., coordinator of the ALLOCATE Skin group of the ERN Skin and chair of the ARHS Task Force group of the EADV. He is the editor of the EADV News and the copyright co-holder of IHS4 on behalf of the EHSF e.V. His previous employer has received disease-relevant clinical study fees from Boehringer-Ingelheim, BMS, Brandenburg Medical School Theodor Fontane, EADV, European Union, German Federal Ministry of Education and Research, GSK, Incyte, InflaRx, MSD, Novartis, Sanofi and UCB Pharma for his participation as a clinical investigator.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study did not require any patient information; hence no ethical review or approval was required. All the involved dermatologists who were part of the consensus gave their approval for the study to be published and were involved in the writing and\/or revision of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}